Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2004

01-09-2004 | Poster presentation

Abnormal collagen type I production in osteoarthritic subchondral bone is associated with a reduced capacity of osteoblasts to mineralize in vitro

Authors: I Aubry, A Delalandre, JC Fernandes, J Martel-Pelletier, J-P Pelletier, D Lajeunesse

Published in: Arthritis Research & Therapy | Special Issue 3/2004

Login to get access

Excerpt

Osteoarthritis (OA) is characterized by cartilage loss, synovial inflammation, osteophytes, and abnormal subchondral bone remodeling including sclerosis. Bone sclerosis in OA is due to an abundant osteoid collagen matrix. Collagen type 1 synthesis is increased in in vivo OA bone tissue and there is an abnormal ratio of collagen type 1α1 chains (Coll1α1) to Coll1α2 chains in this tissue. The mechanisms responsible for this abnormal osteoid matrix remain unknown. …
Metadata
Title
Abnormal collagen type I production in osteoarthritic subchondral bone is associated with a reduced capacity of osteoblasts to mineralize in vitro
Authors
I Aubry
A Delalandre
JC Fernandes
J Martel-Pelletier
J-P Pelletier
D Lajeunesse
Publication date
01-09-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 3/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1422

Other articles of this Special Issue 3/2004

Arthritis Research & Therapy 3/2004 Go to the issue

Poster presentation

Oral treatment with PD-0200347, an α2δ ligand, reduces the development of experimental osteoarthritis by inhibiting the chondrocytes metalloproteases and inducible nitric oxide synthase gene expression and synthesis

Poster presentation

Advanced glycation endproducts in the development of osteoarthritis

Oral presentation

Adverse effects of rheumatoid arthritis on bone remodeling

Poster presentation

Regulatory role of C5a anaphylatoxin on the Fcγ Rs effector system in immune complex-induced diseases

Poster presentation

Systemic lupus erythematosus is characterized by faulty B-cell tolerance in the germinal centers

Poster presentation

Lymphoid chemokine expression in Sjogren's syndrome: relationship with the lymphoid organization of the periductal inflammatory aggregates
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits